KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Tax Provisions (2016 - 2025)

Resmed (RMD) has disclosed Tax Provisions for 16 consecutive years, with $103.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 40.51% year-over-year to $103.6 million, compared with a TTM value of $332.8 million through Dec 2025, up 16.26%, and an annual FY2025 reading of $276.8 million, up 13.53% over the prior year.
  • Tax Provisions was $103.6 million for Q4 2025 at Resmed, up from $98.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $103.6 million in Q4 2025 and bottomed at $35.5 million in Q4 2021.
  • Average Tax Provisions over 5 years is $60.6 million, with a median of $52.8 million recorded in 2023.
  • The sharpest move saw Tax Provisions soared 45.5% in 2024, then decreased 29.73% in 2025.
  • Year by year, Tax Provisions stood at $35.5 million in 2021, then skyrocketed by 37.26% to $48.8 million in 2022, then rose by 3.85% to $50.7 million in 2023, then surged by 45.5% to $73.7 million in 2024, then surged by 40.51% to $103.6 million in 2025.
  • Business Quant data shows Tax Provisions for RMD at $103.6 million in Q4 2025, $98.3 million in Q3 2025, and $78.3 million in Q2 2025.